The UK Cell Therapy Technologies Market was valued at $127.5 Million in 2025 and projected to reach to $238.3 Million by 2030, representing a compound annual growth rate of 13.3%. The UK cell therapy technologies market is poised for sustained expansion driven by increasing clinical adoption, growing investment in regenerative medicine, and the country's position as a leading biotech hub.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK cell therapy technologies market is valued at $127.5 million in 2025, with a projected CAGR of 13.3%, reaching $238.3 million by 2030, outpacing the global growth rate of 12.4%.
The UK's robust regulatory framework through the MHRA (Medicines and Healthcare products Regulatory Agency) provides a competitive advantage, enabling faster approval pathways for innovative cell therapy products and attracting international biotech investments.
The UK hosts world-leading regenerative medicine research institutions and significant government funding initiatives, positioning it as a global center for cell therapy innovation and clinical trial development.
The NHS's advanced healthcare infrastructure and established clinical networks provide ideal conditions for cell therapy adoption, implementation, and real-world evidence generation across multiple therapeutic areas.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MEDIA, SERA, AND REAGENTS (Product) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.4% from 2025 to 2030 |
| Largest Segment | T-CELLS (Cell Type) |
| Market Size Base Year (Billions) | ~USD 4.41 (2025) |
| Revenue Forecast (Billions) | ~USD 7.91 (2030) |
| Segments Covered | Product, Type, Process, Cell Type |
4 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 108.5 | 111.3 | 122.2 | 135.5 | 151.7 | 171.8 | 197.3 | 230.3 | 13.5 |
| CELL BANKS | 18.3 | 18.7 | 19.9 | 21.4 | 23.1 | 25.4 | 28.1 | 31.7 | 9.8 |
| CROS & CMOS | 88.2 | 90.7 | 98.4 | 107.8 | 119.3 | 133.6 | 151.6 | 175 | 12.2 |
| RESEARCH INSTITUTES | 30.5 | 31 | 33.4 | 36.3 | 39.9 | 44.3 | 49.9 | 57.1 | 11.3 |
| TOTAL | 245.4 | 251.8 | 274 | 300.9 | 334 | 375 | 426.9 | 494.1 | 12.5 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| GENERAL ELECTRIC | United States | Public Company | Commercial Engines & Services,Defense & Propulsion Technologies,Additive, Components, and Other Systems, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, instruments, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor materials, specialty gases, display and OLED materials, delivery equipment), |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, filtration, fluid management, process chromatography),Lab products and services (weighing, pipettes, lab filtration, water systems, microbiological testing),Advanced analytics and PAT (BLI, cytometry screening, SPR, live-cell imaging, data analytics), |
| FRESENIUS SE & CO. KGAA | Germany | Public Company | Fresenius Helios (hospitals and care centers),IV generics and IV fluids,Clinical nutrition (enteral and parenteral), |
| CORNING INCORPORATED | United States | Public Company | Optical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials (mobile, semiconductor optics, aerospace, defense, sunglasses, shielding), |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
| BIO-TECHNE | United States | Public Company | Protein Sciences reagents and proteomic tools,Diagnostics controls, calibrators, and assays,Spatial biology and advanced genomic assays, |
| GENSCRIPT | Hong Kong | Public Company | Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products, |
| MAXCYTE | United States | Public Company | ExPERT GTx and VLx (large and very large scale therapeutic applications),ExPERT STx (flow electroporation for protein production and drug development),ExPERT ATx (static electroporation for small to medium scale), |
General Electric is a diversified American industrial conglomerate founded in 1892 that operates across multiple sectors including power, renewable energy, aviation, and healthcare. As a public company, GE employs approximately 57,000 people globally and maintains a significant presence in industrial manufacturing and technology.
Merck KGaA is a German pharmaceutical, chemical, and life sciences company founded in 1668 with approximately 59,077 employees worldwide. Operating as a public company, Merck KGaA serves customers across the healthcare, life science, and performance materials sectors.
Sartorius AG is a German life sciences and laboratory equipment company founded in 1870 with 14,242 employees. As a public company, Sartorius specializes in bioprocess solutions, laboratory instruments, and weighing technology for pharmaceutical and biotechnology industries.
Fresenius SE & Co. KGaA is a German healthcare company founded in 1912 with 177,783 employees, making it one of the largest healthcare service providers globally. Operating as a public company, Fresenius provides dialysis products and services, hospital care, and pharmaceutical products.
Corning Incorporated is an American materials science company founded in 1851 with 67,200 employees that specializes in glass, ceramics, and optical physics. As a public company, Corning serves industries including telecommunications, display technology, environmental solutions, and life sciences.
Terumo Corporation is a Japanese medical device and pharmaceutical company founded in 1921 with 30,591 employees. As a public company, Terumo develops and manufactures products for cardiovascular systems, general hospital care, transfusion and cell therapy, and vascular intervention.
Bio-Techne is an American life sciences company founded in 1976 with 3,100 employees that provides tools and reagents for research and diagnostics. Operating as a public company, Bio-Techne serves the biotechnology, pharmaceutical, and academic research sectors.
GenScript is a Hong Kong-based biotechnology company founded in 2002 with 6,165 employees specializing in synthetic biology and life science research services. As a public company, GenScript provides gene synthesis, protein production, and drug discovery solutions to pharmaceutical and research organizations.
MaxCyte is a small American biotechnology company founded in 1998 with 91 employees focused on cell engineering and manufacturing technologies. Operating as a public company, MaxCyte develops platforms for ex vivo cell therapy production.
The UK cell therapy technologies market is valued at $127.5 million in 2025 and is projected to grow to $238.3 million by 2030.
The UK cell therapy technologies market is growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2030.
Key growth drivers in the UK include the NHS commitment to precision medicine, strong regulatory support from the MHRA, increasing clinical trial activity, and expanding manufacturing infrastructure for cell therapies.
The UK is positioned as a leading hub for cell therapy innovation within Europe, supported by advanced healthcare infrastructure, strong academic institutions, and government investment in regenerative medicine research.
Cell therapy applications in the UK span oncology, immunology, regenerative medicine, and rare genetic disorders, with growing adoption across NHS trusts and private healthcare providers.
This research study utilized extensive secondary sources, directories, and databases to identify and collect valuable information for analyzing the global cell therapy technologies market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to gather and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was primarily used to identify and collect information for the comprehensive, technical, market-oriented, and commercial study of the cell therapy technologies market. The secondary sources used for this study include FDA (US Food and Drug Administration), EMA (European Medicines Agency), NIH (National Institutes of Health), ClinicalTrials.gov, PMDA (Pharmaceuticals and Medical Devices Agency, Japan), MHRA (Medicines and Healthcare products Regulatory Agency, UK), European Society of Gene and Cell Therapy (ESGCT), California Institute for Regenerative Medicine (CIRM), World Health Organization (WHO), International Society for Cell & Gene Therapy (ISCT), CBER (Center for Biologics Evaluation and Research), NIH Regenerative Medicine Program, National Medical Products Administration (NMPA), China, Health Canada – Biologics and Genetic Therapies Directorate (BGTD), Eurostat, Factiva, and GLOBOCAN, ScienceDirect; research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations, among others. These sources were also utilized to gather key information about major players, market classification, and segmentation, as well as industry trends, regional/country-level markets, market developments, and technological perspectives.
After acquiring foundational knowledge about the global cell therapy technologies market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from biopharmaceutical & biotechnology companies, CROs and CMOs, research institutes, and cell banks. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell therapy technologies market. These methods were also used extensively to estimate the size of various market segments. The research methodology used to estimate the market size includes the following:
After determining the overall market size through the estimation process, the total market was divided into several segments and subsegments.

After determining the market size through the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, as applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Cell therapy is a transformative area that represents a groundbreaking advancement in modern medicine, leveraging living cells to repair, replace, or regenerate damaged tissues and treat a wide range of diseases. This innovative approach involves introducing functional cells into a patient’s body to restore health, offering solutions for conditions that were once considered untreatable. With applications spanning autologous therapies, which utilize a patient’s cells, and allogeneic therapies, offering scalable off-the-shelf solutions, cell therapy is transforming healthcare delivery. The report encompasses a range of media, sera, reagents, cell engineering products, cell therapy equipment, software, and other products utilized at various stages of cell therapy, including cell collection, manufacturing, expansion, and storage.
Full forecast, segment splits, and company analysis for all Cell Therapy Technologies Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report